Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10065


Purpose:

The purpose of this study is to test a new imaging agent called 89Zr-J591 (stands for humanized antibody called J591, that is attached to a radioactive material called Zirconium-89) in patients with glioblastoma multiforme.


Criteria:

Inclusion Criteria: - Patient age > 25 years old and < 80 years old - Patients with reoccurrence of brain tumor - The principal investigator or co-PI must review MRI and CT findings based on the radiologic assessment provided they meet the following imaging criteria (as established in the clinical trial 09-177): OR - Patients with newly diagnosed GBM and one of the following options: - Eligible for surgery after the last research scan. - Significant residual disease after initial surgery - The principal investigator or co-PI must review MRI and CT findings and agree with the presence of significant residual disease - Treatment (non-surgical) naïve - Karnofsky Performance Score ≥ 70 Exclusion Criteria: - Laboratory values: - Serum creatinine >2.5 mg/dL. - AST (SGOT) >2.5x ULN. - Bilirubin (total) >1.5x ULN. - Serum calcium >11 mg/dL. - Pregnant or breastfeeding (if a female is of childbearing potential, and unsure of pregnancy status, a standard pregnancy test should be done). - If an initial biopsy demonstrates neoplasm other than GBM - Presence of any other co-existing condition which, in the judgment of the investigator, might increase the risk to the subject. - Presence of serious systemic illness, including: uncontrolled inter-current infection, uncontrolled malignancy, significant renal disease, or psychiatric/social situations, which might limit compliance with study requirements - Prior treatment. - Other serious illness (es), which might preclude completion of this, study or interfere with determination of causality of any adverse effects experienced in this study.


NCT ID:

NCT02410577


Primary Contact:

Principal Investigator
Joseph Osborne, MD,PhD
Memorial Sloan Kettering Cancer Center


Backup Contact:

N/A


Location Contact:

New York, New York 10065
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 19, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.